Premium
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
India Globalization Capital Inc is an investment holding company. The company's operating segment includes Infrastructure and Life Sciences. It generates maximum revenue from the Life Sciences segment. The Infrastructure Business segment involves the execution of construction contracts, the rental o... India Globalization Capital Inc is an investment holding company. The company's operating segment includes Infrastructure and Life Sciences. It generates maximum revenue from the Life Sciences segment. The Infrastructure Business segment involves the execution of construction contracts, the rental of heavy construction equipment, and the purchase and resale of physical commodities used in infrastructure. The Life Sciences Segment includes biopharmaceuticals and Over the Counter Products Geographically, it derives a majority of revenue from Hong Kong and also has a presence in India. Show more
- Interim results indicate cognitive improvement in the active treatment group compared to placebo - No serious adverse events or deaths reported in the trial IGC Pharma, Inc. (NYSE American:...
IGC-AD1 demonstrates the potential to modify tau and improve spatial memory Data supports the initiation of clinical trials investigating IGC-AD1 as a treatment for Alzheimer's disease IGC...
IGC Pharma, Inc. (NYSE American: IGC) ("IGC Pharma" or the "Company") announced today that the Company is advancing its proprietary formulation, IGC-AD1, toward clinical trials as a potential...
IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) announces that during its Annual Meeting of Stockholders scheduled for and convened on August 23, 2023 (the “Annual Meeting”), all...
IGC-1C Targets Tau Protein and GLP-1 Receptor, Offering a Multi-Pathway Approach to Neurodegenerative and Metabolic Disease Treatment IGC Pharma, Inc. (NYSE American: IGC) ("IGC Pharma" or the...
- Artificial Intelligence Modelling Reveals New Possibilities for Metabolic and Neurological Therapies - IGC Pharma, Inc. (NYSE American: IGC) ("IGC Pharma" or the "Company") today announced that...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0179 | 5.08378301619 | 0.3521 | 0.38 | 0.3521 | 269705 | 0.37023077 | CS |
| 4 | -0.0016 | -0.43057050592 | 0.3716 | 0.423 | 0.3308 | 451973 | 0.37224737 | CS |
| 12 | -0.0103 | -2.70838811465 | 0.3803 | 0.43 | 0.33 | 336082 | 0.37521706 | CS |
| 26 | -0.068 | -15.5251141553 | 0.438 | 0.498 | 0.33 | 357651 | 0.38738353 | CS |
| 52 | 0.0739 | 24.9577845323 | 0.2961 | 0.9099 | 0.265 | 496102 | 0.43677447 | CS |
| 156 | -0.66 | -64.0776699029 | 1.03 | 1.16 | 0.2501 | 363961 | 0.51411295 | CS |
| 260 | -0.2305 | -38.3846794338 | 0.6005 | 4.65 | 0.2501 | 1869030 | 1.95195216 | CS |
| Symbole | Prix | Vol. |
|---|---|---|
| AAPYKurv Yield Premium Strategy Apple AAPL ETF | US$ 27,5187 (0,00%) | 0 |
| AAPXT Rex 2X Long Apple Daily Target ETF | US$ 33,64 (0,00%) | 0 |
| AAPRInnovator Equity Defined Protection ETF 2 Yr to April 2026 | US$ 26,455 (0,00%) | 0 |
| AAAUGoldman Sachs Physical Gold ETF Shares | US$ 25,855 (0,00%) | 0 |
| AAAAlternative Access First Priority CLO Bond ETF | US$ 25,05 (0,00%) | 0 |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
